Iguratimod is a drug for treating rheumatoid arthritis, jointly developed with Eisai Co., Ltd. It was approved for manufacturing and marketing in Japan on June 29, 2012, and launched in the domestic market in September 2015.
Iguratimod is an oral drug that underwent domestic clinical trials in combination with methotrexate, the standard care for rheumatoid arthritis, and became the first agent in Japan that demonstrated efficacy when administered in combination with MTX on rheumatoid arthritis patients. Iguratimod is a drug that provides a new treatment option for rheumatoid arthritis.
The new licensing partner TR-Pharm is an affiliate of Russia's powerful pharmaceutical company R-Pharm. TR-Pharm has been established as a development and manufacturing base for Turkey, Middle East and North Africa. TR-Pharm has over 10 agents in development pipeline, focusing on the field of oncology, virology and inflammatory diseases for business expansion.
Under the licensing agreement, Toyama Chemical provides TR-Pharm with the exclusive rights for developing, manufacturing and marketing iguratimod for the treatment of rheumatoid arthritis in Turkey, Middle East and North Africa, in exchange for a lump-sum payment and royalty. Toyama Chemical, a subsidiary of Fujifilm holdings Corporation, specializes in pharmaceutical research and development, and strives to contribute to further development of global health care through new drug development.